# Chapter 16: Schizophreniform Disorder

## The Biological and Neurological Basis of Schizophreniform Disorder

## Introduction

Schizophreniform Disorder occupies a critical, albeit temporally defined, position within the schizophrenia spectrum and other psychotic disorders (Reichenberg & Seligman, 2016). Diagnostically, it is characterized by a symptom profile identical to that of schizophrenia, including the presence of positive symptoms such as delusions and hallucinations, negative symptoms like avolition and affective flattening, and disorganized speech or behavior (Dodd, 2007; Buckley & Foster, 2014). The defining distinction lies in its duration: the disturbance, including prodromal, active, and residual phases, must last at least one month but less than six months (Dodd, 2007; Bravo et al., 2024). If symptoms persist beyond this six-month threshold, the diagnosis is typically changed to schizophrenia (Dodd, 2007; Pereira, 2021). Conversely, if the episode resolves within one month, a diagnosis of Brief Psychotic Disorder may be more appropriate (Unknown, 2017).

This durational criterion positions Schizophreniform Disorder as an intermediate diagnosis, bridging the gap between transient psychotic states and chronic schizophrenia (Reichenberg & Seligman, 2016). The clinical course is notably heterogeneous; a significant portion of individuals, approximately one-third, experience a full recovery within the six-month period, returning to their baseline level of functioning (Dodd, 2007; Bravo et al., 2024). However, for the remaining two-thirds, the disorder serves as a provisional diagnosis for what will ultimately evolve into schizophrenia or schizoaffective disorder (Dodd, 2007). This prognostic variability underscores the profound clinical and scientific importance of understanding the biological mechanisms at play during this critical window. Is Schizophreniform Disorder a distinct biological entity, a prodromal phase of a chronic illness, or a heterogeneous collection of conditions with divergent neurobiological trajectories (Bravo et al., 2024)?

The available research literature specifically investigating the neurobiology of Schizophreniform Disorder is limited. Consequently, much of our current understanding is extrapolated from the extensive body of research on schizophrenia, a disorder with which it shares its core psychopathology (Buckley & Foster, 2014; Marcello & Silverstein, 2010). This chapter will adopt this prevailing paradigm, reviewing the biological and neurological basis of schizophrenia as described in the available literature to illuminate the likely mechanisms underlying Schizophreniform Disorder. This approach assumes that the neurobiological disturbances observed in schizophrenia are also present, perhaps in a nascent or evolving state, in individuals who meet the criteria for Schizophreniform Disorder. Throughout this chapter, we will explore the implicated neurotransmitter systems, neural circuits, genetic predispositions, and structural and functional brain abnormalities. By leveraging the schizophrenia model, we aim to construct a comprehensive, evidence-based overview of the biological underpinnings of Schizophreniform Disorder, while acknowledging the inherent limitations of this proxy-based approach and highlighting the critical need for future research focused specifically on this intermediate psychotic condition.

## Neurobiological Systems

The neurobiological investigation of psychotic disorders, including schizophrenia and by extension Schizophreniform Disorder, has historically been dominated by the study of neurotransmitter systems (Dodd, 2007). The development of effective antipsychotic medications provided the initial and most enduring clues into the underlying neurochemistry of psychosis (Ereshefsky et al., 1990). The prevailing theories, derived largely from schizophrenia research, point to a complex dysregulation across multiple neurotransmitter pathways, with the dopamine system being of central importance (Dodd, 2007; Ereshefsky et al., 1990).

### The Dopamine Hypothesis

The dopamine hypothesis, in its simplest form, posits that an excess of dopamine activity is linked to the positive symptoms of schizophrenia, such as hallucinations and delusions (Dodd, 2007; Buckley & Foster, 2014). This hypothesis is supported by several lines of evidence. First, pharmacological agents that block dopamine receptors, particularly the D2 receptor subtype, effectively lessen psychotic symptoms (Dodd, 2007). These antipsychotic drugs are the mainstay of treatment for both schizophrenia and Schizophreniform Disorder (Bravo et al., 2024; Dodd, 2007). Second, drugs that stimulate dopamine release, such as amphetamine and cocaine, can induce psychotic symptoms in individuals without a pre-existing psychotic disorder and can exacerbate them in those with schizophrenia (Dodd, 2007; Avellaneda Ojeda et al., 2023).

The neurobiology is, of course, more complex than a simple global excess of dopamine. Modern formulations of the hypothesis suggest a more nuanced picture of dysregulation. For instance, it is theorized that positive symptoms arise from hyperactivity of the dopaminergic system in mesolimbic areas, while negative and cognitive symptoms may be related to hypoactivity (reduced function) of dopamine in mesocortical regions, particularly the prefrontal cortex (Dodd, 2007; Ereshefsky et al., 1990). This aligns with clinical observations where negative symptoms like avolition and blunted affect are often more refractory to treatment than positive symptoms (Price & Heil, 1987; Buchanan, 2006).

Five main types of dopamine receptors (D1-D5) have been identified, each with distinct distributions and functions (Dodd, 2007). D2 receptors, located in high concentrations in the striatum, are the primary target of most antipsychotic medications (Dodd, 2007). Positron emission tomography (PET) studies measuring receptor occupancy have shown that "typical" or first-generation antipsychotics achieve their effect by occupying a high percentage (around 78%) of D2 receptors, with little effect on D1 receptors (Dodd, 2007). In contrast, "atypical" or second-generation antipsychotics tend to have lower D2 receptor occupancy (around 48%) but higher occupancy of D1 receptors (38%-52%), which is thought to contribute to their different side-effect profile, particularly a lower incidence of extrapyramidal symptoms (EPS) (Dodd, 2007; Kasantikul & Kanchanatawan, 2007). Given that Schizophreniform Disorder presents with the same active-phase symptoms as schizophrenia, it is presumed that this same mesolimbic dopamine hyperactivity underlies its positive symptomatology (Dodd, 2007; Jibson et al., 2004). Indeed, patients with Schizophreniform Disorder typically respond rapidly to antipsychotic treatment, often faster than patients with established schizophrenia (Bravo et al., 2024).

Postmortem studies in individuals with schizophrenia have sometimes revealed increased dopamine or its metabolite, homovanillic acid, in limbic areas and the left amygdala, although these findings may be a consequence of long-term antipsychotic treatment (Dodd, 2007). The most consistent finding from functional neuroimaging in schizophrenia is an increased density of D2 receptors in the striatum and nucleus accumbens (Dodd, 2007), providing further support for dopaminergic dysregulation in the core pathophysiology of psychosis.

### Serotonin, Norepinephrine, and Glutamate Systems

While dopamine remains central, it is clear that other neurotransmitter systems are also involved, creating a more complex picture of neurotransmission imbalance (Ereshefsky et al., 1990). Serotonin (5-HT) hyperactivity has been implicated, partly due to the psychotomimetic effects of serotonergic hallucinogens like LSD, which produce altered states of consciousness and perception (Willner, 1984; Cole & Katz, 1964). Furthermore, many atypical antipsychotics, such as clozapine and risperidone, are potent antagonists of serotonin 5-HT2A receptors in addition to their D2 blockade (Dodd, 2007; Ereshefsky et al., 1990). This dual action is believed to contribute to their efficacy, particularly against negative symptoms, and their lower propensity to cause EPS (Dodd, 2007; Moore et al., 1992). The complex interplay between serotonin and dopamine systems, particularly in the frontal cortex and striatum, suggests that serotonergic dysfunction may modulate dopaminergic pathways, contributing to the overall state of dysregulation (Dodd, 2007).

Norepinephrine hyperactivity is another proposed neurochemical abnormality in schizophrenia (Dodd, 2007). This is consistent with the state of hyperarousal often seen in acute psychosis (Battaglia et al., 2007) and the frequent comorbidity with anxiety symptoms (Tollefson et al., 1993). Some antipsychotic agents have effects on noradrenergic receptors, which may contribute to their sedative and anxiolytic properties (Dodd, 2007).

More recently, hypotheses involving the glutamate system, the brain's primary excitatory neurotransmitter, have gained prominence. This line of inquiry was spurred by the observation that antagonists of the NMDA glutamate receptor, such as phencyclidine (PCP) and ketamine, can induce a psychotic state that closely mimics both the positive and negative symptoms of schizophrenia (Walder et al., 2014; Nasrallah, 2009). This suggests that hypofunction of the NMDA receptor system could be a key upstream pathological event, leading to downstream dysregulation of dopamine and other neurotransmitter systems (Harnessing brain activity at adolescence prevents later schizophrenia development, 2019). This hypothesis is particularly compelling as it may better account for the cognitive deficits and negative symptoms that are poorly explained by the simple dopamine hyperactivity model (Gallagher & Young, 2024).

### GABAergic System

The brain's primary inhibitory neurotransmitter, γ-aminobutyric acid (GABA), also appears to be dysfunctional in schizophrenia (Dodd, 2007). Neuropathological studies have pointed to a loss of GABAergic interneurons, particularly in the hippocampus and prefrontal cortex (Dodd, 2007; Ereshefsky et al., 1990). This loss of inhibitory tone could lead to disinhibition of cortical circuits and contribute to cognitive disorganization and a reduced signal-to-noise ratio in information processing (Schwartz, 1990). A dysfunctional inhibitory mechanism, potentially involving GABA, has been proposed to underlie information processing deficits that occur very early (around 100 milliseconds) after a stimulus is presented (Schwartz, 1990; Shul'gina, 2011). Reduced GABAergic function could lead to downstream hyperactivity of other systems, including dopamine, creating a state of cortical hyperexcitability (Dodd, 2007). The complex interplay of these excitatory and inhibitory systems highlights that the neurobiology of psychosis is not a matter of a single neurotransmitter, but a widespread dysregulation of neural communication. Given the symptomatic identity, these same complex interactions are presumed to be active in Schizophreniform Disorder (Dodd, 2007).

## Genetic and Molecular Basis

The development of Schizophreniform Disorder, like schizophrenia, is not the result of a single cause but rather a complex interplay of genetic vulnerability and environmental factors (Dodd, 2007; Buckley & Foster, 2014). The "two-hit" or "multiple-hit" hypothesis has strong support, suggesting that an individual may possess a genetic predisposition but will not manifest the disorder unless other environmental or developmental insults are encountered (Dodd, 2007). This model provides a framework for understanding why not all individuals with a genetic risk develop the illness and explains the variable onset and course, including the potential for recovery in Schizophreniform Disorder or progression to chronic schizophrenia (Dodd, 2007; Jablensky, 2012).

### Heritability and Familial Risk

Evidence for a strong genetic component in the schizophrenia spectrum is robust and comes primarily from family, twin, and adoption studies (Dodd, 2007; Tiganov, 1999). These studies, while focused on schizophrenia, provide the best available proxy for understanding the heritable risk for Schizophreniform Disorder. The risk of developing schizophrenia is significantly elevated in the relatives of affected individuals. For instance, siblings of individuals with schizophrenia have approximately a 10% lifetime risk of developing the disorder, a stark increase from the general population risk of about 1% (Dodd, 2007; Buckley & Foster, 2014). The risk is even more pronounced in offspring. A child with one parent diagnosed with schizophrenia has about a 6% chance of developing the illness (Dodd, 2007). This risk escalates dramatically to 46% if both parents have schizophrenia (Dodd, 2007).

Twin studies provide the most compelling evidence for genetic influence. Monozygotic (identical) twins, who share nearly 100% of their genetic material, have a concordance rate for schizophrenia of nearly 50% (Dodd, 2007). This means that if one identical twin has schizophrenia, the other has a roughly 50% chance of also developing the disorder. In contrast, dizygotic (fraternal) twins, who share on average 50% of their genes (the same as non-twin siblings), have a concordance rate of about 17% (Dodd, 2007). The fact that the concordance rate for identical twins is not 100% strongly indicates that non-genetic factors, such as environmental exposures, play a crucial role in the etiology of the disorder (Dodd, 2007; Stringer et al., 2015). This incomplete penetrance is consistent with the "multiple-hit" model, where genetic liability requires an additional environmental or developmental trigger to manifest clinically (Dodd, 2007). Individuals who develop Schizophreniform Disorder likely share this same genetic liability, with the specific outcome—recovery or progression—potentially being influenced by the nature of the genetic loading, the presence of protective factors, or the severity of environmental insults (Dodd, 2007; Chase & Silverman, 1941).

### Candidate Genes and Molecular Mechanisms

The search for specific genes underlying the risk for schizophrenia spectrum disorders has been a monumental effort, revealing a highly polygenic architecture rather than a single "schizogene" (Meehl, 1989; Stringer et al., 2015). Numerous genetic linkages have been proposed, implicating multiple chromosomal regions, including 3p, 5q, 6p, 6q, 8p, 10p, 13q, 15q, 18p, and 22q (Dodd, 2007). This wide array of potential loci underscores the genetic complexity and heterogeneity of the disorder (Stringer et al., 2015).

Research has also pointed to the involvement of large trinucleotide repeats, specifically CAG/CTG repeats on chromosomes 17 and 18, as a potential molecular mechanism contributing to risk (Dodd, 2007). Such repeat expansions are known to be involved in other neurodegenerative and neuropsychiatric disorders, such as Huntington's disease, and may contribute to neural dysfunction through various pathogenic processes (Fink, 2005).

While the specific genes remain elusive and their individual effects small, many of the candidate genes identified are involved in critical neurodevelopmental processes, synaptic function, and neurotransmitter systems, particularly the dopamine and glutamate pathways (Rico, 2012; Ereshefsky et al., 1990). For example, genes related to dopamine metabolism (like COMT), dopamine receptors, and glutamate receptors have been investigated extensively (Dodd, 2007). The genetic predisposition for schizophrenia spectrum disorders, therefore, likely translates into subtle but widespread alterations in brain development and function, creating a state of vulnerability (Meehl, 1989; Fish, 1978). This "schizotaxia," a hypothesized neurointegrative defect, may manifest as a range of outcomes from subclinical schizotypal personality traits to full-blown psychosis, depending on the interaction with other genetic and environmental factors (Meehl, 1989; Lenzenweger, 2018). It is plausible that the initial clinical manifestation of this genetic liability is often a Schizophreniform episode, with the subsequent course determined by the resilience of the individual's neurobiological systems and the presence of additional risk or protective factors (Dodd, 2007).

## Brain Structure and Function

Neuroimaging has become an indispensable tool for investigating the neurobiological substrates of psychotic disorders, providing in vivo evidence of brain abnormalities in individuals with schizophrenia (Dodd, 2007). Although studies focusing specifically on Schizophreniform Disorder are scarce in the provided literature, the structural and functional findings in schizophrenia offer a crucial window into the likely neuropathology of this diagnostically related condition. The prevailing view is that the brain abnormalities seen in chronic schizophrenia are not solely the result of long-term illness or treatment, but rather reflect a neurodevelopmental vulnerability that is present at or before the first episode of psychosis (Dodd, 2007; Fletcher, 2003).

### Structural Neuroimaging Findings

One of the most consistent and frequently replicated findings in structural magnetic resonance imaging (MRI) studies of schizophrenia is the enlargement of the cerebral ventricles, particularly the third and lateral ventricles (Dodd, 2007). This enlargement is thought to be an indirect marker of reduced brain tissue volume in surrounding areas (Dodd, 2007). It is often present at the first episode of psychosis and, in some cases, even in individuals at high risk for the disorder, suggesting it is an early feature of the disease process rather than a consequence of chronicity or medication (Fletcher, 2003).

Correspondingly, selective reductions in the volume of specific brain regions have been widely reported (Dodd, 2007). The frontal lobe, which is critical for executive functions, planning, and regulation of behavior, often shows a decrease in size (Dodd, 2007; Jurado & Junqué, 2001). Limbic regions, which are central to emotion and memory, are also consistently implicated, with volume reductions observed in the hippocampus and medial temporal lobe (Dodd, 2007; DeJong, 1969). The basal ganglia and thalamus, key relay and processing centers in cortical-subcortical circuits, have also been found to be selectively reduced in size (Dodd, 2007). These structural deficits in interconnected frontal, temporal, and subcortical areas support the view of schizophrenia as a disorder of abnormal neural connectivity (Fernández-Egea & Jones, 2023).

Other reported structural abnormalities include sulcal widening, particularly in the frontal and temporal areas, which further points to a loss of cortical gray matter volume (Dodd, 2007). Some studies have also indicated a small but significant difference in total brain and intracranial volume (Dodd, 2007). Furthermore, an increased incidence of developmental anomalies, such as the presence of a cavum septum pellucidum and partial agenesis of the corpus callosum, has been noted (Dodd, 2007). These findings lend strong support to the neurodevelopmental hypothesis of schizophrenia, suggesting that disruptions in early brain formation contribute to the later emergence of the disorder (Dodd, 2007; McEvoy et al., 2020). Given that Schizophreniform Disorder represents an early stage of a psychotic process that may or may not become chronic, it is highly probable that these same structural markers are present in this population, potentially serving as predictors of clinical trajectory (Dodd, 2007). Good prognostic features in Schizophreniform Disorder, such as acute onset and confusion, may be associated with less severe structural abnormalities compared to cases with poor prognostic features like insidious onset, which are more likely to progress to schizophrenia (Dodd, 2007).

### Functional Neuroimaging Findings

Functional neuroimaging techniques, such as positron emission tomography (PET) and functional MRI (fMRI), have provided insights into the patterns of brain activity associated with schizophrenia. A cardinal finding is "hypofrontality," which refers to reduced activity or blood flow in the frontal and prefrontal cortex, particularly during the performance of cognitive tasks that normally engage these regions (Dodd, 2007). This frontal lobe dysfunction is thought to be a key neural correlate of the negative symptoms (e.g., avolition, alogia) and the pervasive neurocognitive deficits (e.g., in working memory and executive function) characteristic of the disorder (Dodd, 2007; Buchanan, 2006; Tamminga et al., 1998).

PET studies have implicated a distributed network of brain regions in the pathophysiology of schizophrenia. This network includes not only various subregions of the frontal cortex (orbital, dorsolateral, medial) but also the anterior cingulate gyrus, thalamus, several temporal lobe subregions, and the cerebellum (Dodd, 2007). The involvement of this wide array of structures further supports the concept of schizophrenia as a disorder of brain-wide dysconnectivity rather than a pathology confined to a single region (Fernández-Egea & Jones, 2023; Nasrallah, 2012).

Functional imaging has also been used to investigate the neural basis of specific psychotic symptoms. For example, PET studies have suggested an anatomical substrate for visual hallucinations, implicating the inferotemporal cortex, a region responsible for the visual recognition of objects and faces (Dodd, 2007). It has been hypothesized that abnormal output from the basal ganglia, driven by increased dopaminergic activity, is relayed through the ventral anterior thalamic nucleus to the inferotemporal cortex, influencing visual processing and causing altered visual perceptions or hallucinations (Dodd, 2007). This model provides a potential mechanism linking the dopamine hypothesis to the subjective experience of specific positive symptoms (Dodd, 2007). Since Schizophreniform Disorder is defined by the same symptom profile as schizophrenia, these functional abnormalities, particularly hypofrontality and dysregulation within cortico-striato-thalamic loops, are considered central to its pathophysiology (Dodd, 2007).

## Developmental Neurobiology

Schizophreniform Disorder, like schizophrenia, is increasingly understood not as a condition with a sudden, de novo onset in early adulthood, but as the culmination of a long-running neurodevelopmental process that begins much earlier in life (Fernández-Egea & Jones, 2023; Isohanni et al., 2020). The clinical syndrome typically presents in early adulthood (Dodd, 2007; Buckley & Foster, 2014), but the "seeds of schizophrenia may be sown in early life with aberrant childhood development in multiple domains" (Fernández-Egea & Jones, 2023). This developmental perspective is critical for understanding the emergence of Schizophreniform Disorder and its potential progression.

### Premorbid and Prodromal Phases

The period before the first frank psychotic episode is often characterized by a series of subtle but significant deviations from normal development (Häfner, 2002; Yung, 2011). A prolonged prodromal phase frequently precedes the active symptoms of psychosis (Dodd, 2007; Pereira, 2021). This phase can last for months or even years and is often marked by a decline in academic and social functioning (Pereira, 2021; Häfner, 2002). Individuals may exhibit social withdrawal, a loss of interest in self-care, and awkwardness in motor skills (Dodd, 2007; Salokangas & McGlashan, 2008). These non-specific symptoms, such as sleep disturbance, irritability, lowered mood, and anxiety, can easily be mistaken for other adolescent difficulties or psychiatric conditions like depression (Yung, 2011; Benarous, 2016; Remschmidt, 2002).

In some cases, the prodrome can be traced back even further to premorbid abnormalities. Studies have found that up to 25% of individuals who develop schizophrenia may have shown schizoid personality traits before the illness developed (Dodd, 2007). Early developmental delays in cognitive, language, and communication domains have also been noted as potential early manifestations of the disorder (Groisman & Seminatore, 2003). These early dysfunctional states, which can be psychopathologic, neurologic, or somatovegetative, may reflect an instability of functional systems during a latent stage of the disease process (Volovik & Sheĭnina, 1983). The onset of Schizophreniform Disorder, therefore, often represents the point at which these subtle, long-standing vulnerabilities cross a threshold into clinically significant psychosis (Schultze-Lutter, 2016; Häfner, 2002). The presence of good premorbid functioning is considered a positive prognostic factor, suggesting that a more severe or pervasive neurodevelopmental disruption may predict a poorer outcome, such as progression to schizophrenia (Dodd, 2007).

### Critical Periods and Neurodevelopmental Insults

The "two-hit" hypothesis posits that a primary, early-life insult (the "first hit"), often genetic or occurring in utero, establishes a vulnerability in the developing brain (Dodd, 2007). This vulnerability may remain latent until a "second hit," typically occurring during the critical period of adolescence or early adulthood, triggers the onset of psychosis (Harnessing brain activity at adolescence prevents later schizophrenia development, 2019). This second hit can be an environmental stressor, substance use, or the normal neurodevelopmental processes of this life stage, such as synaptic pruning and myelination in the prefrontal cortex (Dodd, 2007; Fernández-Egea & Jones, 2023).

Several early environmental factors have been associated with an increased risk for schizophrenia spectrum disorders. A history of injury at birth may be a contributing factor (Dodd, 2007). Similarly, a "season of birth" effect has been consistently observed, with a higher proportion of individuals with schizophrenia being born in the early spring or winter months (Dodd, 2007), possibly reflecting maternal exposure to viral infections during the second trimester of gestation, a critical period for fetal neural development (Groisman & Seminatore, 2003). These early insults are thought to disrupt normal brain maturation, leading to the subtle structural and functional abnormalities discussed previously, such as reduced cortical volume and abnormal connectivity (Dodd, 2007).

Adolescence represents another critical period. The significant brain reorganization that occurs during this time may unmask the latent vulnerability established by the first hit (Harnessing brain activity at adolescence prevents later schizophrenia development, 2019). The typical age of onset for schizophrenia—average of 21 years for men and 27 for women (Dodd, 2007)—coincides with the final stages of this brain maturation process. The emergence of Schizophreniform Disorder during this window is thus consistent with a neurodevelopmental model where the brain's capacity to compensate for early insults is finally overwhelmed, leading to the expression of psychotic symptoms (Fernández-Egea & Jones, 2023). The heterogeneity in outcomes for Schizophreniform Disorder—with some recovering and others progressing—may reflect differences in the severity of the initial neurodevelopmental insult, the nature of the "second hit," and the individual's underlying genetic and neurobiological resilience (Dodd, 2007; Carpenter & Kirkpatrick, 1988).

## Treatment Mechanisms

The management of Schizophreniform Disorder, like acute schizophrenia, is primarily centered on pharmacological intervention aimed at rapidly controlling psychotic symptoms and restoring psychosocial functioning (Dodd, 2007; Bravo et al., 2024). The biological basis of these treatments is rooted in the modulation of the same neurotransmitter systems implicated in the pathophysiology of the disorder, most notably the dopamine system (Ereshefsky et al., 1990). Understanding the mechanisms of action of these agents provides critical insight into the neurobiology of the condition they are designed to treat.

### Antipsychotic Pharmacodynamics: D2 Receptor Blockade

The mainstay of treatment for the acute symptoms of Schizophreniform Disorder is antipsychotic medication (Dodd, 2007; Bravo et al., 2024). The therapeutic action of these drugs is fundamentally linked to the dopamine hypothesis of psychosis (Dodd, 2007). The primary mechanism of action for virtually all effective antipsychotics is the blockade of postsynaptic dopamine D2 receptors (Dodd, 2007; Ereshefsky et al., 1990). By antagonizing these receptors, particularly in the mesolimbic pathway, these medications are thought to reduce the excessive dopaminergic activity that underlies positive symptoms like hallucinations and delusions (Dodd, 2007; Buckley & Foster, 2014). This mechanism is supported by the strong correlation between the clinical potency of antipsychotic drugs and their affinity for the D2 receptor (Ereshefsky et al., 1990).

Antipsychotics are broadly divided into two classes: first-generation (FGA) or "typical" agents, and second-generation (SGA) or "atypical" agents (Dodd, 2007; Ereshefsky et al., 1990). Typical antipsychotics, such as haloperidol and chlorpromazine, are potent D2 receptor antagonists (Dodd, 2007). PET studies have demonstrated that they achieve their clinical effect at a D2 receptor occupancy of approximately 78% (Dodd, 2007). However, this high degree of D2 blockade, particularly in the nigrostriatal pathway, is also responsible for a high incidence of extrapyramidal side effects (EPS), such as parkinsonism, dystonia, and akathisia (Dodd, 2007; Kasantikul & Kanchanatawan, 2007). In some cases, these medications may even worsen neurocognitive functioning (Dodd, 2007).

### Atypical Antipsychotics: Serotonin-Dopamine Antagonism and Beyond

Atypical antipsychotics, such as risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole, were developed to provide similar or superior efficacy with a more favorable side-effect profile (Dodd, 2007; Montes & Rey, 2009). While they also block D2 receptors, their mechanism is more complex. A key feature of many SGAs is their potent antagonism of serotonin 5-HT2A receptors (Ereshefsky et al., 1990). This combined serotonin-dopamine antagonism is thought to be crucial to their "atypicality" (Dodd, 2007). Serotonergic blockade may enhance dopamine release in certain brain regions, such as the prefrontal cortex and the nigrostriatal pathway, which could potentially alleviate negative symptoms and mitigate the risk of EPS, respectively (Dodd, 2007; Ereshefsky et al., 1990).

PET studies confirm this different receptor profile, showing that atypicals achieve efficacy at a lower D2 receptor occupancy (around 48%) while also engaging D1 and other receptor subtypes (Dodd, 2007). This broader receptor-binding profile may contribute to their purported efficacy against a wider range of symptoms and may improve neurocognitive impairment in some patients (Dodd, 2007). For this reason, atypical antipsychotics are generally considered first-line treatment for Schizophreniform Disorder and first-episode psychosis (Dodd, 2007; Bravo et al., 2024). Clozapine, the prototype atypical, has a unique profile with relatively low D2 affinity but high affinity for multiple other receptors; it is reserved for treatment-resistant cases due to the risk of severe agranulocytosis (Dodd, 2007; Moore et al., 1992).

### Treatment Course and Implications

In Schizophreniform Disorder, antipsychotic treatment is typically administered for a period of 3 to 6 months (Bravo et al., 2024). A notable clinical observation is that patients with this disorder often respond more rapidly to medication than those with chronic schizophrenia (Bravo et al., 2024). This may suggest that the underlying neurobiological processes are more plastic or reversible in the earlier stages of psychosis (Dodd, 2007). After the resolution of the acute episode, maintenance therapy for at least 1 to 2 years is generally recommended following an initial psychotic episode to prevent relapse (Dodd, 2007).

In addition to antipsychotics, other psychopharmacological agents may be used as adjuncts. Benzodiazepines can be beneficial for managing acute agitation or anxiety (Dodd, 2007; Battaglia et al., 2007), while mood stabilizers or antidepressants may be considered if significant mood symptoms are present, though care must be taken as antidepressants can sometimes induce or worsen manic symptoms in vulnerable individuals (Dodd, 2007; Swann, 2009). The differential response to these various agents underscores the neurobiological heterogeneity of psychotic disorders and highlights the need for personalized treatment strategies based on the specific symptom profile of the individual patient (Dodd, 2007).

## Future Directions

The study of Schizophreniform Disorder, as a distinct entity on the psychosis spectrum, presents both significant challenges and unique opportunities for advancing our understanding of the neurobiology of schizophrenia and related conditions. While our current knowledge is heavily reliant on extrapolations from schizophrenia research, future investigations must focus directly on the Schizophreniform population to delineate the specific biological mechanisms that govern its variable course and outcome (Dodd, 2007).

A primary goal for future research is the identification of robust biological markers that can predict clinical trajectory. Given that two-thirds of individuals diagnosed with Schizophreniform Disorder will eventually progress to schizophrenia or schizoaffective disorder, while one-third will fully recover (Dodd, 2007), the ability to distinguish between these groups at initial presentation would be of immense clinical value. Such markers could guide treatment decisions, inform prognosis, and facilitate the development of targeted preventive interventions (Salokangas & McGlashan, 2008). Prospective longitudinal studies are critically needed. These studies should enroll patients at their first psychotic episode who meet criteria for Schizophreniform Disorder and follow them over time, employing a multi-modal approach that integrates clinical, neuroimaging, genetic, and neurophysiological assessments (Dodd, 2007; Jablensky, 2012).

Neuroimaging studies should aim to clarify whether the structural and functional brain abnormalities observed in schizophrenia, such as ventricular enlargement and hypofrontality (Dodd, 2007), are present to the same degree in all individuals with Schizophreniform Disorder. It is plausible that those who recover may have less pronounced or more localized abnormalities, or may exhibit greater neuroplasticity and compensatory brain activity, compared to those who develop a chronic course (Dodd, 2007). Advanced imaging techniques could explore dynamic changes in brain connectivity and function over the course of the disorder and in response to treatment, providing a more nuanced view of the underlying pathophysiology (Fletcher, 2003).

Genetic research must move beyond simply identifying risk loci for schizophrenia and begin to investigate how genetic profiles interact with environmental factors to influence the specific phenotype of a psychotic episode, including its duration and outcome (Stringer et al., 2015). The "two-hit" model provides a useful framework (Dodd, 2007), but the specific molecular pathways that differentiate a transient psychotic response from the onset of a chronic illness are unknown. Identifying genes related to neural resilience, synaptic plasticity, or immune response could provide crucial insights into the mechanisms of recovery.

Furthermore, the neurochemical basis of good prognostic features in Schizophreniform Disorder, such as the presence of confusion, disorganization, and prominent mood symptoms at the peak of the episode (Dodd, 2007), warrants investigation. These features, which align with the characteristics of "cycloid psychoses" or "bouffée délirante" in other nosological systems, may point to a different underlying neurobiology, perhaps with greater involvement of affective or limbic circuits and less severe prefrontal cortical deficits, compared to cases characterized by insidious onset and prominent negative symptoms (Marneros & Pillmann, 2004; Sáiz Ruiz & Dolengevich-Segal, 2004). Investigating neurotransmitter systems beyond dopamine, such as glutamate and GABA, may be particularly fruitful in this regard (Dodd, 2007).

Finally, the development of novel therapeutic interventions should be informed by a deeper understanding of the biology of this early phase of psychosis. If specific mechanisms of recovery can be identified, it may be possible to develop treatments that promote these pathways, potentially increasing the proportion of individuals who achieve full remission. This could involve pharmacological agents that enhance neuroplasticity or targeted psychosocial interventions designed to reduce environmental stress and bolster cognitive and social functioning (Dodd, 2007; Compton & Broussard, 2010). Ultimately, the goal is to move beyond a diagnosis based solely on symptom duration and toward a biologically informed classification that can predict outcome and guide personalized, preventive care for individuals experiencing their first episode of psychosis (Salokangas & McGlashan, 2008).

## Conclusion

Schizophreniform Disorder, defined by its schizophrenia-like symptomatology and intermediate duration of one to six months, represents a critical juncture in the course of psychotic illness (Dodd, 2007; Reichenberg & Seligman, 2016). While it serves as a provisional diagnosis for what often becomes chronic schizophrenia, the fact that a substantial minority of individuals achieve complete recovery highlights its status as a heterogeneous condition with diverse underlying mechanisms and outcomes (Dodd, 2007; Bravo et al., 2024). Due to a paucity of direct research, our current biological understanding of Schizophreniform Disorder is largely inferred from the vast literature on schizophrenia.

This proxy-based model points to a complex neurobiology rooted in a convergence of genetic predisposition and environmental insults, consistent with a neurodevelopmental "multiple-hit" framework (Dodd, 2007). The core pathophysiology is believed to involve dysregulation of multiple neurotransmitter systems, with hyperactivity of the mesolimbic dopamine pathway being a central mechanism underlying the positive psychotic symptoms (Dodd, 2007; Ereshefsky et al., 1990). The therapeutic efficacy of D2 receptor antagonists provides strong pharmacological evidence for this hypothesis (Dodd, 2007). However, evidence also implicates dysfunction in serotonin, norepinephrine, glutamate, and GABA systems, suggesting a broader network-level disturbance (Dodd, 2007).

Structurally and functionally, the brains of individuals on the schizophrenia spectrum exhibit characteristic abnormalities, including ventricular enlargement, reduced volume in frontal and temporal cortices, and hypofrontality during cognitive tasks (Dodd, 2007). These alterations are thought to be early developmental markers of vulnerability, present at or before the first psychotic episode, rather than consequences of chronic illness (Fletcher, 2003). It is within this context of a predisposed and vulnerable brain that the clinical syndrome of Schizophreniform Disorder emerges, typically during the critical developmental period of late adolescence and early adulthood (Häfner, 2002).

The fundamental challenge remains the biological heterogeneity concealed within the Schizophreniform diagnosis (Bravo et al., 2024). The good prognostic indicators—such as acute onset, confusion, and prominent affective symptoms—may signify a distinct neurobiological subtype that is more amenable to resolution, compared to the insidious onset and prominent negative symptoms that often predict progression to chronic schizophrenia (Dodd, 2007). Future research must prioritize the direct investigation of the Schizophreniform population through longitudinal studies to identify biomarkers that can differentiate these trajectories. A deeper understanding of the genetic, molecular, and neural circuit mechanisms that mediate recovery versus chronicity will be essential for transforming clinical practice from a retrospective, duration-based diagnosis to a prospective, biologically-informed model of early intervention and personalized care. Until then, the neurobiology of schizophrenia remains our most valuable, albeit imperfect, guide to understanding this enigmatic and pivotal psychotic disorder.

## References

1. Adetunji, B., Matthews, M., Basil, B., & Oyemade, A. (2007). "Bipolar Family". The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0211e
2. Agarwal, K., Yadav, A. K., Verma, P., & Kaur, B. (2021). DYSTHYMIA AND it’s HOMOEOPATHIC MANAGEMENT. Journal of Emerging Technologies and Innovative Research.
3. Agudelo, D., Spielberger, C. D., & Buela‐Casal, G. (2007). La depresión: ¿un trastorno dimensional o categorial?. Salud Mental.
4. Ahmadbegi, S., Jafarian, A. A., Aliasl, J., & Rostami, A. (2016). Typical Absence Seizure Similarity to “Shokhous” in Iranian Traditional Medicine. Iranian Red Crescent Medical Journal. https://doi.org/10.5812/ircmj.21048
5. AIa, T. (1999). [The main clinico-neurological syndromes of prolonged hypokinesia].. PubMed.
6. Ajayi, O., Esangbedo, A., Lawal, A. A., Olanrewaju, A. O., Ojo, T. O., & Talabi, O. (2023). Moral Injury, Trance and Possession State or a Schizophrenic Illness. a Case report. BJPsych Open. https://doi.org/10.1192/bjo.2023.359
7. Alarcón, R. D. (2016). El diagnóstico precoz de las depresiones de la vejez. Deleted Journal. https://doi.org/10.15581/021.12.6450
8. Alexandre, S., Misery, L., Dutray, S., Chastaing, M., Consoli, S.-M., Audra, H., Bauer, D., Bertolus, S., Callot, V., Cardinaud, F., Corrin, E., Féton-Danou, N., Malet, R., Touboul, S., & Consoli, S. (2007). Functional Itch Disorder or Psychogenic Pruritus: Suggested Diagnosis Criteria From the French Psychodermatology Group. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-0266
9. Ali, S., Patel, M., Avenido, J., Bailey, R. K., Jabeen, S., & Riley, W. J. (2011). Hallucinations: Common Features and Causes: Awareness of Manifestations, Nonpsychiatric Etiologies Can Help Pinpoint a Diagnosis. Current psychiatry.
10. Alvarado, R., Shilling, S., & Jorquera, M. J. (2015). Uso de la Intervención Critical Time Intervention en personas con primer episodio de psicosis. Revista de la Facultad de Ciencias Médicas de Córdoba. https://doi.org/10.31053/1853.0605.v72.n4.13845
11. Amores, F. B. C., Pérez, G. P. L., Torres, N. A. C., & Carpio, V. D. P. C. (2023). Sleep pattern impairment in nursing students according to NANDA. Medwave. https://doi.org/10.5867/medwave.2023.s1.uta111
12. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
13. Anderson, M. (2010). Benzodiazepines for prolonged seizures. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/adc.2009.176321
14. Antón, R., Conde, L. A., Gardeazábal, M. B., Ozcariz, P. A., Zariquiey, N. C., Figueiredo, N. D. S., & Salinas, V. F. (2021). Cycloid psychosis. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.1702
15. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
16. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
17. As, B., On, C., & NIu, R. (2014). [Bipolar depression in the clinic of schizophrenia].. PubMed.
18. As, T. (1999). [Current concept of schizophrenia: state of the art].. PubMed.
19. Bansal, R., & Sheldon, S. H. (2008). Parasomnias in Childhood. CRC Press eBooks. https://doi.org/10.3109/9781420048087-26
20. Barakat, B., Agosti, R., Ruggeri, E., Tonini, V., Cervellera, M., Guidetti, E., Cevenini, M., Imbrogno, A., Fabbri, D., Pareo, I., Fucili, A., Corinaldesi, R., Stanghellini, V., Pezzilli, R., & Giorgio, R. D. (2012). Atypical presentation of acute idiopathic megacolon in a 14-year-old patient. Emergency Care Journal. https://doi.org/10.4081/ecj.2012.3.5
21. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
22. Barnhill, J. W., Loewenstein, R. J., Simeon, D., & Lewis‐Fernández, R. (2023). Dissociative Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615375295.jb08
23. Barrio, P., Seeman, M. V., & González-Rodríguez, A. (2021). Alcohol and Psychosis: A Narrative Review of the Prevalence, Clinical Manifestations, and Management of Alcohol-related Psychotic Symptoms. Current Psychiatry Research and Reviews. https://doi.org/10.2174/2666082217666210602111739
24. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
25. Basu, D., Sharma, A., & Nebhinani, N. (2009). Disulfiram-induced delirium: diagnostic dilemma.
26. Basura, G. J., Adams, M. E., Monfared, A., Schwartz, S., Antonelli, P. J., Burkard, R., Bush, M. L., Bykowski, J., Colandrea, M., Derebery, J., Kelly, E. A., Kerber, K. A., Koopman, C. F., Kuch, A. A., Marcolini, E. G., McKinnon, B. J., Ruckenstein, M. J., Valenzuela, C. V., Vosooney, A., ... Buchanan, E. M. (2020). Clinical Practice Guideline: Ménière’s Disease. Otolaryngology. https://doi.org/10.1177/0194599820909438
27. Battaglia, J., Robinson, D. G., & Citrome, L. (2007). The Treatment of Acute Agitation in Schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852900026146
28. Bd, S. (1990). Early information processing in schizophrenia.. Psychiatric medicine.
29. Benarous, X. (2016). Affective symptoms and emerging psychotic disorder in adolescents. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1217
30. Bentes, C., & Pimentel, J. G. (2012). Estado de mal convulsivo. Aspectos fisiopatológicos e clínicos.. Acta Médica Portuguesa. https://doi.org/10.20344/amp.1154
31. Berg, J., & Grimeland, J. (2012). Obsessive-compulsive disorder in disguise—Case report. Open Journal of Psychiatry. https://doi.org/10.4236/ojpsych.2012.23026
32. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
33. Bitter, I. (2020). Definitions and measurement of negative symptoms in schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198840121.003.0001
34. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
35. Borchers, A., & Cagle, L. A. (2018). Look‐Alike Causes of Respiratory Distress. https://doi.org/10.1002/9781119028994.ch50
36. Borchert, A., Möddel, G., & Schilling, M. (2009). Teaching Video Neuro <i>Images</i> : Paroxysmal kinesigenic dyskinesia. Neurology. https://doi.org/10.1212/wnl.0b013e3181a92b66
37. Bosanac, B., Dominik, P., Gabrić, P., Hrstić, A., Ključarić, D. K., Kužina, I., Sović, M. S., & Vandek, M. (2020). Lexical-semantic categorisation in patients of schizophrenia. https://doi.org/10.17605/osf.io/5z9c4
38. Bradic, L., Lokmić-Pekić, I., & Dzevad, B. (2018). Psychiatric comorbidity in patients with posttraumatic stress disorder and enduring personality change after catastrophic experience. https://doi.org/10.26226/morressier.5b68175cb56e9b005965c22b
39. Bravo, B., González, S. M. B., Portilla, N. O., Laynez, M. E. G., Gutiérrez, N. S., & Sánchez, F. G. (2024). Schizophreniform disorder. Clinical manifestations and diagnosis. Purposely a case. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2024.1542
40. Breckwoldt, M., & Zahradnik, H. P. (1989). Pramenstrnelles Syndrom nnd Dysmenorrho.
41. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
42. Bromberger, J. T. (1998). Gender and Depression. https://doi.org/10.1093/oso/9780195113969.003.0003
43. Bromberger, J. T., & Woods, N. F. (2009). Nonhormonal Factors Associated with Psychiatric Morbidity during the Menopausal Transition and Midlife. Key issues in mental health (Online)/Key issues in mental health (Print). https://doi.org/10.1159/000209601
44. Bromet, E. J., & Naz, B. (2006). Diagnostic variability in the early course of schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198510840.003.0008
45. Brust, J. C. (2001). Music and the Neurologist. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2001.tb05730.x
46. Buchanan, R. W. (2006). Persistent Negative Symptoms in Schizophrenia: An Overview. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbl057
47. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
48. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
49. Burke, A., Yaari, R., Tariot, P. N., Dougherty, J., Fleisher, A., & Brand, H. (2012). The Shadow People. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12alz01398
50. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
51. Cambra, P. R. (2021). Trastorno mental grave, pacientes con esquizofrenia.. Revista Sanitaria de Investigación.
52. Campoy, A. T., Rotger, M. Y., Gutiérrez, L. R. D. L. H., & Pastorelli, R. V. (2011). ¿Psicosis mental injertada o retraso mental? A propósito de un caso.. Psiquiatria.com.
53. Canbulat, N., & Sonay, A. (2012). Pain Management and Nursing Approaches in Pediatric Oncology. InTech eBooks. https://doi.org/10.5772/32053
54. Cano, J. F., & García, J. D. (2005). Insomnio: enfoque diagnóstico y terapéutico. IATREIA. https://doi.org/10.17533/udea.iatreia.4131
55. Carpenter, W. T., & Kirkpatrick, B. (1988). The Heterogeneity of the Long-Term Course of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/14.4.645
56. Carvajal-Lohr, A., Flores‐Ramos, M., Montejo, S. I., & Vidal, C. G. (2016). Los trastornos de ansiedad durante la transición a la menopausia. Perinatología y Reproducción Humana. https://doi.org/10.1016/j.rprh.2016.03.003
57. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
58. Casher, M. I., & Bess, J. D. (2020). The Inpatient with Dual Diagnosis (Co-Occurring Disorder). Cambridge University Press eBooks. https://doi.org/10.1017/9781108656672.009
59. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
60. Charmaz, K. (2007). Chronic Illness and Disability. The Blackwell Encyclopedia of Sociology. https://doi.org/10.1002/9781405165518.wbeosc035
61. CHASE, L. S., & Silverman, S. (1941). PROGNOSTIC CRITERIA IN SCHIZOPHRENIA. American Journal of Psychiatry. https://doi.org/10.1176/ajp.98.3.360
62. Chaudhry, H., Arshad, N., Niaz, S., Cheema, F., Iqbal, M., & Mufti, K. (2005). Fifteen-year follow-up of conversion disorder. International Psychiatry. https://doi.org/10.1192/s1749367600007517
63. Chu, B., Marwaha, K., Sanvictores, T., & Ayers, D. (2019). Physiology, Stress Reaction. StatPearls.
64. Clark, M., & McKinlay, J. (2009). Coma, Confusion, and Agitation in Intensive Care. Competency-based critical care. https://doi.org/10.1007/978-1-84882-070-8_11
65. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
66. Clayton, A., Dennerstein, L., Pyke, R. E., & Sand, M. (2010). Flibanserin: A Potential Treatment for Hypoactive Sexual Desire Disorder in Premenopausal Women. Women s Health. https://doi.org/10.2217/whe.10.54
67. Coccolini, F., Improta, M., Picetti, E., Vergano, L. B., Catena, F., Angelis, N. D., Bertolucci, A., Kirkpatrick, A. W., Sartelli, M., Fugazzola, P., Tartaglia, D., & Chiarugi, M. (2020). Timing of surgical intervention for compartment syndrome in different body region: systematic review of the literature. World Journal of Emergency Surgery. https://doi.org/10.1186/s13017-020-00339-8
68. Coghill, D., Bonnar, S., Duke, S., Graham, J., & Seth, S. (2009). Obsessive compulsive disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199234998.003.0020
69. Cole, J., & Katz, M. M. (1964). THE PSYCHOTOMIMETIC DRUGS. AN OVERVIEW.. PubMed.
70. Cole, J., & Katz, M. M. (1964). The Psychotomimetic Drugs. JAMA. https://doi.org/10.1001/jama.1964.03060230086021
71. Compton, M. T., & Broussard, B. (2010). Psychosocial Treatments for Early Psychosis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195372496.003.0016
72. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
73. Cooper, L., Copeland, S., Dailey, S., Downey, D., Petersen, M. C., Stimson, C., & Dyke, D. C. V. (2008). Feeding and swallowing dysfunction in genetic syndromes. Developmental Disabilities Research Reviews. https://doi.org/10.1002/ddrr.19
74. Cordeiro, Q., Zung, S., & Vallada, H. (2008). Pisa syndrome induced by rapid increase and high dosage of risperidone. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2008000600026
75. Cáceres, F., Baca, G. H. R., Osorto, L. J. R., Godoy, K. J. Á., Hernández, G. R. O., Barahona, R. D. S., Sorto, N. D. Z., Suárez, M., Anduray, A. S. M., Mendoza, K. V. J., & Vargas, G. H. R. (2024). Síndrome Convulsivo. Religación Press eBooks. https://doi.org/10.46652/religacionpress.195.c296
76. Dahlem, M. A., Mair, T., & Müller, S. C. (2004). Spatio-Temporal Aspects of a Dynamical Disease: Waves of Spreading Depression. Birkhäuser Basel eBooks. https://doi.org/10.1007/978-3-0348-7895-1_42
77. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
78. Daley, M., & Cannon, T. D. (2010). Childhood Psychosis. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0172
79. Dalvi, A., Lyons, K. E., & Pahwa, R. (2012). Secondary dystonia. CRC Press eBooks. https://doi.org/10.3109/9781841848525-20
80. Danilova, S. (2009). Expert Evaluation of «Another Unhealthy Conditions». European Psychiatry. https://doi.org/10.1016/s0924-9338(09)71057-0
81. Debiais, S., Bonnaud, I., Ferreira-Maldent, N., Mercier, E., & Toffol, B. D. (2009). NEUROPSYCHIATRIC DISORDERS REVEALING PRIMARY ANTIPHOSPHOLIPID SYNDROME IN AN ELDERLY PATIENT. Neurology. https://doi.org/10.1212/wnl.0b013e3181a0fd69
82. DeJong, R. N. (1969). Memory Loss due to Hippocampal Lesions. Archives of Neurology. https://doi.org/10.1001/archneur.1969.00480100015001
83. Delgado, S., Wassenaar, E., & Strawn, J. R. (2011). Does Your Patient Have a Psychiatric Illness or Nonverbal Learning Disorder? Clinical Clues Help Differentiate Overlapping Symptoms and Syndromes. Current psychiatry.
84. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
85. Derbyshire, S., & Bremner, J. D. (2009). Impact Of Functional Visceral And Somatic Pain/Stress Syndromes On Cingulate Cortex. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198566960.003.0023
86. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
87. Desmiwarti, D. (2019). KEHAMILAN DENGAN GANGGUAN JIWA. Andalas obstetrics and gynecology journal. https://doi.org/10.25077/aoj.1.2.93-99.2017
88. Ding, K., Gupta, P. K., & Diaz‐Arrastia, R. (2016). Epilepsy after Traumatic Brain Injury. CRC Press, Taylor and Francis Group eBooks.
89. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
90. Dodick, D. W., & Roarke, M. C. (2007). Familial Hemiplegic Migraine: Permanent Attack‐Related Neurologic Deficits. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2007.00889.x
91. Donati, F., Carrara, C., Casetta, C., Giudice, R. D., Zalaffi, M., Cornali, M., Maestri, D., Sarasso, S., & D’Agostino, A. (2020). M6. REDUCED READINESS POTENTIAL AS A NEUROPHYSIOLOGICAL CORRELATE OF SELF-DISTURBANCES IN EARLY–COURSE PSYCHOSIS: PRELIMINARY FINDINGS FROM A HIGH–DENSITY EEG STUDY. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaa030.318
92. Douglas, M. E., Kim, B., Mayer, G., Crosby, B., & Towe-Goodm, N. (2012). Maternal Depression, Mothering and Child Development. InTech eBooks. https://doi.org/10.5772/38048
93. Dreyer-Oren, S. E., Mitnaul, L., & Holtzheimer, P. E. (2018). Mood Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy25
94. Drmić, S., Vodopija, I., Presečki, P., & Mimica, N. (2009). Involuntary emotional expression disorder - common disorder but rarely diagnosed.
95. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
96. Dubovsky, S., & Thomas, M. P. (1992). Psychotic Depression: Advances in Conceptualization and Treatment. Psychiatric Services. https://doi.org/10.1176/ps.43.12.1189
97. Duletic, N., Mijatovic-Papic, T., Cizmovic, B., & Kusturica, S. (2015). Differential Diagnostic Consideration of the Syndrome of Psychomotor Agitation in Geriatric Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)31130-5
98. Duval, F., Jautz-Duval, M. M., González, F., & Rabia, H. (2010). Bases neurobiológicas de vulnerabilidad psiquiátrica a lo largo de las etapas de la vida hormonal de la mujer. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272010000500005
99. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
100. Ebenezer, I. S. (2015). Affective Disorders 1: Depression. https://doi.org/10.1002/9781118385777.ch6
101. Elble, R. J. (2016). The essential tremor syndromes. Current Opinion in Neurology. https://doi.org/10.1097/wco.0000000000000347
102. Elstner, S., & Diefenbacher, A. (2008). Anpassungsstörungen. Psychiatrie und Psychotherapie up2date. https://doi.org/10.1055/s-2008-1067567
103. Eneman, M., & Sabbe, B. (2006). [Hopelessness in patients with schizophrenia. Suffering from and with schizophrenia].. PubMed.
104. Engel, J. (2001). Vorschlag für ein diagnostisches Schema für Menschen mit epileptischen Anfällen und Epilepsien - Bericht der Task Force der Internationalen Liga gegen Epilepsie (ILAE) zur Klassifikation und Terminologie1 -. Aktuelle Neurologie. https://doi.org/10.1055/s-2001-16868
105. Ereshefsky, L., Tran-Johnson, T., & Watanabe, M. (1990). Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics.. PubMed.
106. Esparcia, A. J., & Marín, M. A. (2009). DSM, MENTAL HEALTH AND PARENTAL ALIENATION SYNDROME.
107. Esquiliano, G. R., Ramírez, I. M., Valdés, A. T., & Aguilar, C. A. T. (2004). Daño neurológico secundario a hipoxia isquemia perinatal. Archivos de neurociencias (México, D.F.).
108. Esteves-Sousa, D., Albuquerque, M., Facucho-Oliveira, J., Santos, P. E. D., Costa, M. S., Chai, M. V., Mendonça, L., & Tropa, J. (2019). ANTIPSYCHOTIC AGENTS, UNDERNEATH THEIR ACTION – STRENGTHS AND SHORTCOMINGS. https://doi.org/10.26226/morressier.5d1a037657558b317a14069b
109. Falcão, J. L. R., Silva, T. S. L. D., & Camões, V. M. D. (2019). A indicação da prescrição da clozapina na esquizofrenia e o risco de agranulocitose: uma revisão literária..
110. Faran, S., Vatine, J., Lazary, A., Ohry, A., Birbaumer, N., & Kotchoubey, B. (2006). Late recovery from permanent traumatic vegetative state heralded by event-related potentials. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2005.076554
111. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
112. Ferguson, E., & Cassaday, H. J. (2001). Theoretical Accounts of Gulf War Syndrome: From Environmental Toxins to Psychoneuroimmunology and Neurodegeneration. Behavioural Neurology. https://doi.org/10.1155/2002/418758
113. Fernández-Egea, E., & Jones, P. B. (2023). Schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.065
114. Feuerecker, R., Dieterich, M., Eckhardt‐Henn, A., & Becker‐Bense, S. (2015). Nicht-organischer Schwindel. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0034-1385272
115. Fiar, Z., Hroudov, J., & Raboch, J. (2012). Neurotransmission in Mood Disorders. InTech eBooks. https://doi.org/10.5772/31831
116. Figueira, M. L. (2010). Are depressive residual symptoms independent of treatments?. Annals of General Psychiatry. https://doi.org/10.1186/1744-859x-9-s1-s72
117. Fink, J. K. (2005). The hereditary spastic paraplegias. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.054
118. Fink, M. (2010). Depressive Mood Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0009
119. Finsterer, J. (2012). Mitochondrion-toxic drugs given to patients with mitochondrial psychoses. Behavioral and Brain Functions. https://doi.org/10.1186/1744-9081-8-45
120. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
121. Fish, B. (1978). Vestibular Hyporeactivity in Infants at Risk for Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1978.01770320057004
122. Fitzgerald, C., & Patten, S. B. (2008). Is Multiple Sclerosis Patient Depressed, Stressed, or Both? How to Sort through Overlapping Symptoms and Provide Appropriate Treatment. Current psychiatry.
123. Fletcher, P. C. (2003). Functional neuroimaging of schizophrenia: from a genetic predisposition to the emergence of symptoms. Brain. https://doi.org/10.1093/brain/awh113
124. Freudenreich, O., Francis, A., & Fricchione, G. L. (2018). Psychosis, Mania, and Catatonia. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl09
125. Frock, B., Williams, A., & Caplan, J. P. (2016). Pseudobulbar Affect: When Patients Laugh or Cry, but Don't Know Why. Current psychiatry.
126. Fujimori, H., Nakatani, Y., & Sakaguchi, M. (1989). Ein Beitrag zur Kenntnis klinischer Verläufe von chronischen Methamphetaminpsychosen. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2007-1001134
127. Gallagher, P., & Young, A. H. (2024). The Management of Neurocognitive Impairment in Mood Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108973922.023
128. García, O. F. D. (2005). Bases Biológicas del Trastorno por Déficit de la Atención e Hiperactividad. Revista Internacional de Psicología. https://doi.org/10.33670/18181023.v6i01.32
129. Garrabé, J., & Cousin, F. (2012). Acute and transient psychotic disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0081
130. Gauthier, C. (2010). [Sexual abuse: a cause for psychosomatic illnesses].. PubMed.
131. Gerlach, M., Mehler‐Wex, C., & Schimmelmann, B. G. (2014). Antipsychotics. https://doi.org/10.1007/978-3-7091-1501-5_5
132. Geuze, R. H. (2016). Motorische ontwikkelingsstoornissen: DCD en dyspraxie.
133. Gi, S. (2011). [Neurophysiological and neurotransmitter mechanisms of behavior inhibition in normal and pathological conditions]..
134. Giacomo, E. D., Moretti, F., Colmegna, F., & Clerici, M. (2023). Obsessive–compulsive disorder as the onset of bipolar disorder in adolescence. Bipolar Disorders. https://doi.org/10.1111/bdi.13373
135. Gilbert‐Barness, E., Debich-Spicer, D., & Opitz, J. M. (2001). Malformation Syndromes. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511547423.010
136. Golden, C. J., & Golden, Z. L. (2004). Traumatic Brain Injury. Routledge eBooks. https://doi.org/10.4324/9780203336960-19
137. González, M. J., Bardanca, M. S. G., Vivanco, E. F., Paz, M. T. A., & Allegue, M. D. (2007). Distonía psicógena: un diagnóstico complejo..
138. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
139. Good, M. I. (1989). Substance-Induced Dissociative Disorders and Psychiatric Nosology. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198904000-00003
140. Goodin, D. S., Frohman, E. M., Garmany, G., Halper, J., Likosky, W., Lublin, F., Silberberg, D. H., Stuart, W. H., & Noort, S. V. D. (2002). Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines: Table 1.. Neurology. https://doi.org/10.1212/wnl.58.2.169
141. Goodwin, D. W. (1969). Psychiatry and the mysterious medical complaint. JAMA. https://doi.org/10.1001/jama.209.12.1884
142. Gorman, J. M. (1992). NEUROPSYCHIATRIC ASPECTS OF HIV INFECTION. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-199201001-00341
143. Greenfield, M. J., Fobian, A. D., Fargason, R. E., & Birur, B. (2024). Optimizing outcomes when treating functional neurological disorder in acute care settings: case reports depicting the value of diagnostic precision and timely and appropriate psychological interventions using an interdisciplinary framework. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1288828
144. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
145. Guerdjikova, A. I., McElroy, S. L., Barger, S. D., Barth, J., Farrelly, S., & Brohan, E. (2019). Recent Advances in Depressive Disorder.
146. Gur, R. E., & Johnson, A. B. (2006). Understanding the Disorder: What it is and What to Expect. https://doi.org/10.1093/oso/9780195182118.003.0002
147. Gutiérrez-Achury, A. M., Vanegas-Vidal, M., Salazar-Díaz, L. I., & Arías, G. M. A. (2009). Factores farmacológicos y no farmacológicos que afectan la adherencia al tratamiento de los pacientes esquizofrénicos dados de alta en la Unidad de Salud Mental del Hospital Universitario de Neiva entre enero y junio del 2008. RFS Revista Facultad de Salud. https://doi.org/10.25054/rfs.v1i2.43
148. Hafeza, M. J., Bourjia, H., & Sroura, H. (2020). Functional Neurological Deficit: one of the most controversial diagnosis- case report of a patient with paraplegia. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2020-02-2305
149. Hainline, B., Gurin, L., & Torres, D. M. (2019). Cognitive Dysfunction Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0034
150. Hainline, B., Gurin, L., & Torres, D. M. (2019). Unmasking Neuropsychiatric Disorders Following Concussion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0035
151. Hatch, G. M., Ashbrook, L., Prather, A. A., & Krystal, A. D. (2019). Snoring: The Case for Molecular Tissue Oximetry. https://doi.org/10.20944/preprints201903.0087.v1
152. Heinz, G. J. A. (2004). Entstehung, Diagnose und Früherkennung schizophrener Erkrankungen. psychoneuro. https://doi.org/10.1055/s-2004-823780
153. Heuzey, M. L. (2004). [Early diagnosis of language disorders].. PubMed.
154. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
155. Häfner, H. (2002). Prodrome, onset and early course of schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544118.011
156. Idar, A. A., Benjilali, L., Saadouni, L., Adali, I., & Manoudi, F. (2020). Neurosarcoïdose à manifestations psychiatriques. A propos d’un cas.
157. Isenberg, K., & Garcia, K. S. (2008). Syndromes of Brain Dysfunction Presenting with Cognitive Impairment or Behavioral Disturbance: Delirium, Dementia, and Mental Disorders Caused by a General Medical Condition. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-252-6_2
158. Isohanni, M., Miettunen, J., & Penttilä, M. (2020). Life span development of schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190653279.003.0017
159. Isometsä, E., Kinnunen, E., Kivekäs, T., Koponen, H., Lappalainen, J., Lindfors, O., Marttunen, M., Pirkola, S., Jousilahti, P., & Tuunainen, A. (2015). [Update on Current Care Guideline: Depression].. PubMed.
160. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
161. İbiloğlu, A. O., Atlı, A., Kaya, M. C., Baran, A. S., & Sır, A. (2016). Psychogenic Gait Disorder After a Stressful Life Event: Case Report. Turkiye Klinikleri Journal of Case Reports. https://doi.org/10.5336/caserep.2015-46732
162. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
163. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
164. Janota, B., Załuska, M., & Papierska, L. (2007). [Personality and behavioural disturbances, with delusional-hallucinatory and delirium episodes in the course of hyponatremia due to paraneoplastic inappropriate vasopressin secretion (SIADH)].. PubMed.
165. Jefferson, J. W. (2001). Social Anxiety Disorder. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.v03n0102
166. Jibson, M. D., Glick, I. D., & Tandon, R. (2004). Schizophrenia and Other Psychotic Disorders. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/foc.2.1.17
167. Jj, D. L. G. M., Francos, D. D., Herrero, H., Al, R. M., & Gómez, L. (1989). [Seasonal variations in dexamethasone suppression test in psychiatric patients].. PubMed.
168. Jung, S. P., & Lee, K. M. (2007). Chronic Fatigue Syndrome. Yeungnam University Journal of Medicine. https://doi.org/10.12701/yujm.2007.24.1.1
169. Kaiser, S., Heekeren, K., & Simon, J. J. (2011). The Negative Symptoms of Schizophrenia: Category or Continuum?. Psychopathology. https://doi.org/10.1159/000325912
170. Kanbara, K., & Fukunaga, M. (2009). Pathology of functional somatic syndrome.
171. Kanchanatawan, B., & Kasantikul, D. (2007). Antipsychotic-induced tardive movement disorders: a series of twelve cases.. PubMed.
172. Kanner, A. M., & Dunn, D. W. (2004). Diagnosis and Management of Depression and Psychosis in Children and Adolescents With Epilepsy. Journal of Child Neurology. https://doi.org/10.1177/088307380401900108
173. Karvonen, J. T., Läksy, K., & Räsänen, S. (2016). [Somatization disorder - an overdiagnosed but underestimated illness].. PubMed.
174. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
175. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.3/shkennedy
176. Ketterer, M. W., & Buckholtz, C. D. (1989). Somatization disorder.. PubMed.
177. Khaikin, Y., & Mercimek‐Andrews, S. (2016). STXBP1 Encephalopathy with Epilepsy.
178. Klein, D. F., & Wender, P. H. (2005). Symptoms of Mood Disorders: Recognizing Biological Depression. https://doi.org/10.1093/oso/9780195156133.003.0002
179. Knaap, M. S. V. D., Depienne, C., Sedel, F., & Abbink, T. E. M. (2015). CLCN2-Related Leukoencephalopathy.
180. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
181. Labalestra, M., Stefaniak, N., Lefèbvre, L., & Besche‐Richard, C. (2018). La mémoire sémantique dans le trouble bipolaire : une revue de la littérature. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2018.0468
182. Labalestra, M., Stefaniak, N., Lefèbvre, L., & Besche‐Richard, C. (2018). La mémoire sémantique dans le trouble bipolaire : une revue de la littérature. Revue de neuropsychologie. https://doi.org/10.3917/rne.103.0213
183. Lam, R. W. (2012). Clinical features and diagnosis. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199692736.003.0004
184. Lansky, M. R. (1989). The Explanation of Impulsive Action. British Journal of Psychotherapy. https://doi.org/10.1111/j.1752-0118.1989.tb01259.x
185. Latta, F., & Cauter, E. V. (2003). Sleep and Biological Clocks. Handbook of Psychology. https://doi.org/10.1002/0471264385.wei0313
186. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
187. Lenzenweger, M. F. (2018). Schizotypy, schizotypic psychopathology and schizophrenia. World Psychiatry. https://doi.org/10.1002/wps.20479
188. Lestari, N. W. D. (2014). TERAPI RESPERIDONE PADA SKIZOFRENIA PARANOID: SEBUAH LAPORAN KASUS. E-Jurnal Medika Udayana.
189. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
190. Lievre, J. L., Schweitzer, R., & Barnard, A. (2012). The subjective experience of negative symptoms: Characteristics of emotional withdrawal.
191. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
192. Linden, M. (2020). Euthymic suffering and wisdom psychology. World Psychiatry. https://doi.org/10.1002/wps.20718
193. Lippi, G., & Favaloro, E. J. (2024). Heparin and Posttraumatic Stress Disorder. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/s-0044-1788697
194. Llorca, P., Chéreau, I., Brousse, G., & Schawn, R. (2004). Troubles psychiatriques d'origine toxique ou alimentaire. EMC - Psychiatrie. https://doi.org/10.1016/j.emcps.2004.04.003
195. Lloyd‐Williams, M. (2004). Are antidepressants effective in cancer patients?. Progress in Palliative Care. https://doi.org/10.1179/096992604225006361
196. Lucassen, P., Ockenburg, S. V., Gans, R. O. B., Rosmalen, J. G., & Hartman, T. O. (2024). [Fatigue].. PubMed.
197. Lütschg, J., Zaugg, C., & Hassink, R. (2012). Neuropédiatrie: Rare mais importante: la dystonie dopa-sensible ou syndrome de Segawa (DYT5). Forum Médical Suisse ‒ Swiss Medical Forum. https://doi.org/10.4414/fms.2012.01378
198. Ma, J., & Junqué, C. (2001). [Criminal behavior after orbitofrontal lesion].. PubMed.
199. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
200. Madruga, M. L. L. H., Melo, G. B., Martins, J. M., Aranha, R. E. L. D. B., Marinho, J. C. R. L., Alves, N. T., Estudo, E., Revisão, U., & Literatura, D. (2018). Estudo Eletroencefalográfico De Indivíduos Com Dor Crônica Decorrente Da Fibromialgia: Uma Revisão Da Literatura. Scientific Research and Reviews. https://doi.org/10.28933/srr-2018-06-28100
201. Mahowald, M. W., Bornemann, M. A. C., & Schenck, C. H. (2010). When and where do synucleinopathies begin?. Neurology. https://doi.org/10.1212/wnl.0b013e3181ec804a
202. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
203. Maletic, V., & DeMuri, B. (2016). Chronic Pain and Depression: Understanding 2 Culprits in Common: Does a Shared Pathophysiology Hold the Key to Managing These Conditions When They Coexist?. Current psychiatry.
204. Manckoundia, P., Soungui, E. N., Tavernier-Vidal, B., & Mourey, F. (2014). Psychomotor disadaptation syndrome. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2014.0450
205. Maramis, M. M. (2009). Mendiagnosis Gangguan Bipolar pada Fase Depresi sejak dini.
206. Maramis, M. M. (2009). Mengenal Gangguan Mood pada Perempuan.
207. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
208. Marcus, L. C., & Plasky, P. (1988). Effects of Drugs on Psychotropic.
209. Mardiyah, A., Sofia, A., Putra, A. B., & Lukman, P. R. (2024). Membedakan Antara Suasana Berkabung dengan Depresi pada Skizofrenia Paranoid Kemunduran Stabil. Journal Of The Indonesian Medical Association. https://doi.org/10.47830/jinma-vol.74.2-2024-1107
210. Marneros, A., & Pillmann, F. (2004). Defining the brief, acute and transient psychotic disorders: the polymorphic psychotic core. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544002.012
211. Marneros, A., Rohde, A., Deister, A., & Steinmeyer, E. (1990). Behinderung und Residuum bei schizoaffektiven Psychosen - Daten, methodische Probleme und Hinweise für zukünftige Forschung. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-2007-1001171
212. Maxwell, R. A., & Eckhardt, S. B. (1990). Imipramine. Drug Discovery. https://doi.org/10.1007/978-1-4612-0469-5_10
213. McEvoy, J. P., Asuzu, K., Bradford, D. W., Freudenreich, O., & Moyer, K. (2020). Treatment and management of patients with schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0065
214. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
215. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
216. Meehl, P. E. (1989). Schizotaxia Revisited. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1989.01810100077015
217. Menéndez, S. F., González, J. M. G., Antuña, V. Á., & Bobes, J. (2016). La demencia del rey Fernando VI y el año sin rey. Revista de Neurología. https://doi.org/10.33588/rn.6211.2016040
218. Mettu, S., Animireddy, D., Kanumuri, P. K., & Muppa, R. (2016). Symptomatic management of a child with cyclic vomiting syndrome. BMJ Case Reports. https://doi.org/10.1136/bcr-2016-216499
219. Meza, E. G. L., Téllez, F. C., Guevara, I. M. A., González-Aragón, M. D. C. F., & Calderón, L. Á. R. (2003). Estado epiléptico no convulsivo asociado a enfermedad de Lafora: presentación de dos casos. Revista de Neurología. https://doi.org/10.33588/rn.3710.2003290
220. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
221. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
222. Miletić, V., & Relja, M. (2009). Dystonia in HIV positive patient.
223. Miller, F. T., Abrams, T., Dulit, R., & Fyer, M. R. (1993). Psychotic Symptoms in Patients With Borderline Personality Disorder and Concurrent Axis I Disorder. Psychiatric Services. https://doi.org/10.1176/ps.44.1.59
224. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
225. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
226. Moch, S. (2011). Dysthymia: more than “minor” depression. South African Pharmaceutical Journal.
227. Montejo, Á. L., Montejo, L., & Baldwin, D. S. (2018). The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry. https://doi.org/10.1002/wps.20509
228. Montes, A. B., & Rey, J. A. (2009). Iloperidone (Fanapt): An FDA-Approved Treatment Option for Schizophrenia. P & T.
229. Monti, M. M., Laureys, S., & Owen, A. M. (2010). The vegetative state. BMJ. https://doi.org/10.1136/bmj.c3765
230. Moore, N. C., LeWitt, P. A., & Gershon, S. (1992). Reduction of dyskinesias and psychiatric disability with clozapine over different time courses. Journal of Psychopharmacology. https://doi.org/10.1177/026988119200600407
231. Morales, D. O. (2019). Muerte encefálica en pediatría..
232. Morylowska-Topolska, J., Ziemiński, R., Molas, A., Gajewski, J., Flis, M., Stelmach, E., & Karakuła‐Juchnowicz, H. (2016). Schizophrenia and anorexia nervosa – reciprocal relationships. A literature review. Psychiatria Polska. https://doi.org/10.12740/pp/onlinefirst/63514
233. Mossaheb, N., Schloegelhofer, M., Schaefer, M., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G., & Amminger, G. P. (2012). Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-215-5_9
234. Moster, R. L., Siever, L. J., & Frangou, S. (2016). Schizophrenia Spectrum and Other Psychotic Disorders. https://doi.org/10.1002/9781118654231.ch15
235. Mota, D. C. M., Barbosa, M., Silva, R. R. D., & Ribeiro, L. H. (2020). SÍNDROME DEL OÍDO MUSICAL Y DEPRESIÓN PSICÓTICA: UN CASO DE DOBLE ACTIVIDAD ALUCINATORIA AUDITIVA..
236. Mucci, A., Bucci, P., Giordano, G. M., Brando, F., & Galderisi, S. (2021). Apathy in schizophrenia: assessment in clinical settings and overlap with other dimensions of impairment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.159
237. Méndez, A. V., Silva, P. L. N. D., Gonçalves, L. G. V., Chaves, S. C. D. S., Veiga, R. M., Mendez, A. E. R., Camilo, M. V. L., Mattos, L. C. D. A. N., Filho, M. R. S., Silva, R. D. G. D., Lima, G. F., Ferreira, C. S., & Santos, L. G. D. S. (2023). NEURONAL DAMAGE IN STATE EPILEPTICUS - LITERATURE REVIEW. International Journal of Health Science. https://doi.org/10.22533/at.ed.1593752318094
238. Nakaya, M., Suwa, H., Komahashi, T., & Ohmori, K. (1999). Is Schizophrenic Symptomatology Independent of the Phase of the Illness?. Psychopathology. https://doi.org/10.1159/000029062
239. Narayan, S. K., Sivaprasad, P., Sahoo, R. N., & Bhuvaneswari, V. (2008). Teaching Video Neuro <i>Image</i> : Chvostek sign with Fahr syndrome in a patient with hypoparathyroidism. Neurology. https://doi.org/10.1212/01.wnl.0000336974.93499.ad
240. Nasrallah, H. A. (2009). Diagnosis 2.0 Are Mental Illnesses Diseases, Disorders, or Syndromes? A Major Challenge for the DSM-V Committees as They Revise the Diagnostic "Bible" of Psychiatric Disorders Is to Determine Whether Mental Illnesses Are Diseases, Disorders, or Syndromes. Current psychiatry.
241. Nasrallah, H. A. (2012). Impaired Mental Proprioception in Schizophrenia. Current psychiatry.
242. Negueruela-López, M., Mardomingo, M. J., & Sánchez, P. G.-P. (2012). Prodromal obsessive-compulsive symptoms in a case of schizophrenia.. PubMed.
243. Nelson, B., & Sass, L. A. (2018). 28.1 VARIETIES OF SELF DISORDER: A BIO-PHENO-SOCIAL MODEL OF SCHIZOPHRENIA. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby014.116
244. Nemani, L. (2018). Syncope. Indian Journal of Cardiovascular Disease in Women. https://doi.org/10.1055/s-0039-1683941
245. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
246. Noeker, M. (2004). [Factitious disorder and factitious disorder by proxy].. PubMed.
247. Nunes, F. D. D., Freitas, P. H. B. D., Pinto, J. A. F., Souza, A. R. S., & Machado, R. M. (2016). Análise da prevalência de Síndrome Metabólica e fatores de risco associados em pacientes com Esquizofrenia Refratária. 12º Congresso Internacional da Rede Unida.
248. Núñez, C., Tobón, S., Vinaccia, S., & Sandín, B. (2006). Evaluación y Terapia Psicológica en la Dispepsia Funcional. Terapia psicológica.
249. Ojeda, A. A. A., Li, B., & Patel, R. (2023). Substance-Induced Psychotic Disorder. Psychiatric Annals. https://doi.org/10.3928/00485713-20230314-01
250. Omar, R. (2016). Mental Disorder or Untreated Pneumonia. Journal of Forensic Biomechanics. https://doi.org/10.4172/2090-2697.1000127
251. Operto, F. F., Pastorino, G. M. G., Padovano, C., Scuoppo, C., Vivenzio, V., & Coppola, G. (2020). Psychogenic Seizures in Adolescents: An “Evergreen” Diagnostic Challenge. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.18662/brain/11.3sup1/131
252. Orsolini, L., Valchera, A., Papanti, D., Vecchiotti, R., & Berardis, D. D. (2016). The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD). European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1060
253. Os, J. V., Praag, H. M. V., & Kloet, E. R. D. (2004). Stress, the brain and depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544422.010
254. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
255. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
256. Oviedo, H. E. C., Andrade, B. A., Nogales, J. R. D., & Apaza, G. S. (2015). SÍNDROME DE CUTTING (AUTOLESIONISMO). Revista de Investigación e Información en Salud. https://doi.org/10.52428/20756208.v10i25.542
257. Ozdemir, D., & Sahni, S. (2019). Conversion Disorder (Functional Neurological Symptom Disorder) Masquerading as Multiple Sclerosis: A Case Report. Cureus. https://doi.org/10.7759/cureus.4893
258. Pan, E., Algül, A., Ebrinç, S., Başoğlu, C., Semiz, Ü., Ateş, M. A., Şenol, M. G., & Çetin, M. (2010). P01-293 - Psychiatric mis-diagnoses and escitolopram treatment of mood and anxiety disorders in myasthenia gravis: a case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)70501-0
259. Panov, G., Dyulgerova, S., Panova, P., & Stefanova, S. (2024). Untangling Depression in Schizophrenia: The Role of Disorganized and Obsessive-Compulsive Symptoms and the Duration of Untreated Psychosis. Biomedicines. https://doi.org/10.3390/biomedicines12112646
260. Paredes, D. F. D., Farfán, J. C. P., Orellana, J. M. F., & Legarda, A. A. B. (2019). Trastorno disfórico premenstrual. RECIAMUC. https://doi.org/10.26820/reciamuc/3.(1).enero.2019.199-217
261. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
262. Pedrós, A., Martí‐Almor, J., Gutiérrez, G., Tenías, J. M., & Ruescas, S. (2009). [Two-year diagnostic stability and prognosis in acute psychotic episodes].. PubMed.
263. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
264. Pereira, J. A. (2021). Teenager with paranoia and hallucinations preceded by a decline in academic and social functioning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0006
265. Perlmutter, R. A. (2004). A Family Approach to Psychiatric Disorders. https://doi.org/10.1176/appi.books.9781615376568
266. Peveler, R. (2002). ABC of psychological medicine: Depression in medical patients. BMJ. https://doi.org/10.1136/bmj.325.7356.149
267. Plotkin, K. E. (2007). Insomnia Caused by Medical Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-042-7_15
268. Politis, M., Wu, K., Molloy, S., Bain, P. G., Chaudhuri, К. R., & Piccini, P. (2010). Parkinson's disease symptoms: The patient's perspective. Movement Disorders. https://doi.org/10.1002/mds.23135
269. Post, R. M. (2002). Introduction: Emotion and Psychopathology. https://doi.org/10.1093/oso/9780195126013.003.0048
270. Potvin, O., Hudon, C., Grenier, S., & Préville, M. (2010). Non-essential symptoms of depression and cognitive impairment no dementia (CIND) in community-dwelling elders without dysphoria or anhedonia. International Psychogeriatrics. https://doi.org/10.1017/s1041610210001419
271. Prasetya, E. B. (2016). PENATALAKSANAAN TERKINI GANGGUAN BIPOLAR.
272. Praško, J., Raszka, M., & Pastucha, P. (2009). Dissociative Disorders - Clinical Manifestation and Management. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)70376-1
273. Price, W. A., & Heil, D. (1987). Treatment of the Negative Symptoms of Schizophrenia with Verapamil. Jefferson Journal of Psychiatry. https://doi.org/10.29046/jjp.005.1.007
274. Putra, H. G. S. A. (2015). GANGGUAN AFEKTIF BIPOLAR MANIA DENGAN PSIKOTIK: SEBUAH LAPORAN KASUS. DOAJ (DOAJ: Directory of Open Access Journals).
275. Pérez, P. S. (2015). El déficit cognitivo en el síndrome de fatiga crónica: factores asociados y evolución.
276. Pérez, Á. M. S., Granados, F. J. V., Salazar, M. H., Méndez, A. Z., & Dávalos, É. M. (2005). Síndrome prefrontal ventromedial. Reporte de caso. Neurología, Neurocirugía y Psiquiatría.
277. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
278. Rascol, O., Payoux, P., Ory, F., Ferreira, J. J., Brefel‐Courbon, C., & Montastruc, J. (2003). Limitations of current Parkinson's disease therapy. Annals of Neurology. https://doi.org/10.1002/ana.10513
279. Reichenberg, L. W., & Seligman, L. (2016). Dissociative Disorders. https://doi.org/10.1002/9781394259465.ch9
280. Reichenberg, L. W., & Seligman, L. (2016). Schizophrenia Spectrum and Other Psychotic Disorders. https://doi.org/10.1002/9781394259465.ch3
281. Reid, K. J., & Zee, P. C. (2004). Circadian Rhythm Disorders. Seminars in Neurology. https://doi.org/10.1055/s-2004-835063
282. Reinders, H. (2002). [The post-whiplash syndrome: don't treat, but unravel].. PubMed.
283. Rico, B. (2012). Finding a druggable target for schizophrenia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1209389109
284. Ristić, A. J., Petrović, I., Vojvodić, N., Janković, S., & Sokić, D. (2004). Phenomenology and psychiatric origin of psychogenic nonepileptic seizures. Srpski arhiv za celokupno lekarstvo. https://doi.org/10.2298/sarh0402022r
285. Rm, S. (1990). [Causalgia in neurologic expert assessment].. PubMed.
286. Rocha, E. A., Mehta, N., Távora‐Mehta, M. Z. P., Roncari, C. F., Cidrão, A. A. D. L., & Elías, J. (2021). Disautonomia: Uma Condição Esquecida – Parte 1. Arquivos Brasileiros de Cardiologia. https://doi.org/10.36660/abc.20200420
287. Rodrigo, M. V. L., Oliver, A. O., Monge, M. P., Fons, V. R., & Cantalejo, Y. D. (2023). Stigma of mental illness in the gypsy ethnic group. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1438
288. Rogers, N. L., & Kloss, J. D. (2004). Medical Conditions and Diseases. CRC Press eBooks. https://doi.org/10.3109/9780203998007-6
289. Rogol, A. M. (2020). Ethical Issues in the Evaluation and Treatment of Depression. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.20200006
290. Roncero, C., & Casas, M. (2004). Trastornos de ansiedad en patología dual.
291. Rosalinda, C., Joy, Shahza, M., & Robert, R. (2012). Ultrastructural Distinctions Between Treatment Responders and Non-Responders in Schizophrenia: Postmortem Studies of the Striatum. InTech eBooks. https://doi.org/10.5772/31396
292. Rozenberg, S. (2008). [Chronic low back pain: definition and treatment].. PubMed.
293. Rubiales, Á. S., Duarte, F. J. B., & Valle, M. L. D. (2015). Es necesario precisar el concepto de sedación. Cuadernos de bioética/Cuadernos de bioética.
294. Ruiz, J. S., & Dolengevich-Segal, H. (2004). [Cycloid psychoses. A case report].. PubMed.
295. Rzeszut, M., & Assael, R. (2020). Differentiating Depression From Demoralization in Organ Transplantation Recipients. Progress in Transplantation. https://doi.org/10.1177/1526924820978602
296. Sabo-Graham, T., & Seay, A. R. (1998). Consultation with the Specialist: Management of Status Epilepticus in Children. Pediatrics in Review. https://doi.org/10.1542/pir.19.9.306
297. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
298. Salleh, M. R. (2002). Is pre-psychotic intervention of schizophrenia realistic ?. PubMed.
299. Salokangas, R. K. R., & McGlashan, T. H. (2008). Early detection and intervention of psychosis. A review. Nordic Journal of Psychiatry. https://doi.org/10.1080/08039480801984008
300. Sarkar, S. (2016). Psychiatric Polypharmacy, Etiology and Potential Consequences. Current Psychopharmacologye. https://doi.org/10.2174/2211556005666160916124719
301. Sass, L. A., Borda, J. P., Madeira, L., Pienkos, E., & Nelson, B. (2018). Varieties of Self Disorder: A Bio-Pheno-Social Model of Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sby001
302. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
303. Schildkrout, B. (2014). Disease #53: Postconcussion Syndrome. https://doi.org/10.1002/9781394260447.ch81
304. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
305. Schildkrout, B. (2014). Mood, Affect, and Emotion. https://doi.org/10.1002/9781394260447.ch4
306. Schneider, S. A., Desai, S., Phokaewvarangkul, O., Roşca, E. C., Sringean, J., Anand, P., Bravo, G. Á., Cardoso, F., Cervantes‐Arslanian, A. M., Chovatiya, H., Crosiers, D., Dijkstra, F., Fearon, C., Grandas, F., Guedj, É., Méndez-Guerrero, A., Hassan, M., Jankovic, J., Lang, A. E., ... Pal, P. K. (2023). COVID19-associated new-onset movement disorders: a follow-up study. Journal of Neurology. https://doi.org/10.1007/s00415-023-11661-x
307. Schultze‐Lutter, F. (2016). First Signs of Emerging Psychosis. Key issues in mental health (Online)/Key issues in mental health (Print). https://doi.org/10.1159/000440912
308. Schwartz, B. (1990). Early information processing in schizophrenia.. PubMed.
309. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
310. Sen, A., & Johnson, M. R. (2020). Epilepsy in later childhood and adulthood. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0575
311. Serradet, A. R. C., Reyes, V. D. L. C. R., & Gómez, N. R. (2018). Conducta homicida en el trastorno esquizotípico. Presentación de un caso. Revista Habanera de Ciencias Médicas.
312. Setyaningrum, D. A. W. (2019). Cedera olahraga serta penyakit terkait olahraga. Jurnal Biomedika dan Kesehatan. https://doi.org/10.18051/jbiomedkes.2019.v2.39-44
313. Sharabyani, S. M. (2016). MENTAL DISORDER AND THEIR TREATMENT. Journal of Fundamental and Applied Sciences. https://doi.org/10.4314/jfas.v8i3s.388
314. Sharma, P. (2021). A Case of Psychogenic Vomiting. https://doi.org/10.35248/2375-4273.21.9.275
315. Sharma, T. (1999). Cognitive effects of conventional and atypical antipsychotics in schizophrenia. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000298103
316. Sharpe, M. (2010). Chronic fatigue syndrome (postviral fatigue syndrome, neurasthenia, and myalgic encephalomyelitis). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260504
317. Sherchan, S., & Joshi, D. (2015). The Man Behind the Royal Massacre. Journal of Nepal Medical Association. https://doi.org/10.31729/jnma.2749
318. Shibasaki, H., Hallett, M., Bhatia, K. P., Reich, S. G., & Balint, B. (2020). Sleep-Related Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190865047.003.0008
319. Shirley, E. A., Hudspeth, L. J., & Maynard, J. R. (2018). Managing Sports-related Concussions From Time of Injury Through Return to Play. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-d-16-00684
320. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
321. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
322. Singh, S. (2015). Mental health in infancy. International Journal of Clinical & Medical Imaging. https://doi.org/10.4172/2376-0249.1000393
323. Soares, W. B., & Lima, A. M. D. O. (2024). First Episode of Psychosis. Advances in medical technologies and clinical practice book series. https://doi.org/10.4018/979-8-3693-0851-6.ch005
324. Soyka, M. (2009). Psychotische Störungen durch Alkohol. Nervenheilkunde. https://doi.org/10.1055/s-0038-1628675
325. Srivastav, D., & Singh, T. B. (2016). Comorbidity Issues and Treatment in Chronic Mental Illness. Advances in psychology, mental health, and behavioral studies (APMHBS) book series. https://doi.org/10.4018/978-1-5225-0519-8.ch005
326. Steineck, G., Bergmark, K., Henningsohn, L., al‐Abany, M., Dickman, P. W., & Helgason, Á. R. (2002). Symptom Documentation in Cancer Survivors as a Basis for Therapy Modifications. Acta Oncologica. https://doi.org/10.1080/02841860260088782
327. Stone, J., & Sharpe, M. (2020). Functional neurological symptom disorder (conversion disorder). Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0133
328. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
329. Stone, W. S., Faraone, S. V., & Tsuang, M. T. (2020). Schizoaffective and schizotypal disorders/acute and transient psychotic disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0061
330. Stringer, S., Nieman, D. H., Kahn, R. S., & Derks, E. M. (2015). Genome-wide association analysis in schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781107337459.010
331. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
332. Swaiman, K. F., & Frank, Y. (1978). Seizure Headaches in Children. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.1978.tb15276.x
333. Swann, A. C. (2009). Pharmacologic Mood Destabilization: <i>Case Vignettes</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900003898
334. Szerman, N., Ferre, F., Basurte-Villamor, I., Vega, P., Mesías, B., Marín-Navarrete, R., & Arango, C. (2020). Gambling Dual Disorder: A Dual Disorder and Clinical Neuroscience Perspective. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2020.589155
335. Szortyka, M. F., Cristiano, V. B., & Belmonte-de-Abreul, P. (2021). The importance of physical intervention in the treatment of patients diagnosed with Schizophrenia. Clinical Psychiatry. https://doi.org/10.36648/2471-9854.21.7.82
336. Sánchez, L. C., Cardona, A., cordoba, S., Silva, A. V., Ruiz, A. C., Ibáñez‐Pinilla, M., Pérez-Olmos, I., & Flórez, J. (2010). Experiencias de estigma en personas con enfermedad mental y su impacto en la autoestima en Colombia. reponame:Repositorio Institucional EdocUR.
337. Tabbane, K., Triki, R., Hajeri, S., Johnson, I., & Chérif, W. (2012). P-1319 - Prodromal symptoms of schizophrenia: a retrospective tunisian study. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)75486-x
338. Tagaya, H., Murayama, N., & Hakamata, Y. (2012). [Definitions and clinical classifications of sleep disorders].. PubMed.
339. TAKANASHI, M. (2010). パーキンソン病の非運動症状. Juntendō Igaku/Juntendo igaku. https://doi.org/10.14789/pjmj.56.444
340. Tamminga, C. A., Buchanan, R. W., & Gold, J. M. (1998). The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199803003-00004
341. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
342. Tatsuzawa, Y., Ono, Y., Takahashi, T., Yoshino, A., & Nomura, S. (2011). Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02207.x
343. Taylor, W. D. (2014). Depression in the Elderly. New England Journal of Medicine. https://doi.org/10.1056/nejmcp1402180
344. Terçariolli, B. I., Rosa, J. M., Vieira, G. P., Cardoso, R., & Lage, P. S. (2024). RESUMO Introdução: Os transtornos mentais são definidos como sendo síndromes caracterizadas por uma perturbação clinicamente expressiva na cognição, na regulação emocional ou no comportamento de um indivíduo, que refletem uma disfunção nos processos psicológicos, biológicos ou de desenvolvimento subjacentes ao funcionamento mental. Estes estão frequentemente associados ao sofrimento ou às incapacidades. Sabe-se que uma das características marcantes de determinados transtornos está relacionada à…. Revista fisio&terapia.. https://doi.org/10.69849/revistaft/fa1020240911111905
345. Thomsen, T., & Miyasaki, J. M. (2012). Psychogenic Movement Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_7
346. Thyer, B. A., & Wodarski, J. S. (2007). Social work in mental health : an evidence-based approach. Wiley eBooks.
347. Tickner, N., Apps, J., Keady, S., & Sutcliffe, A. (2012). An overview of drug therapies used in the treatment of dystonia and spasticity in children. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/archdischild-2011-301170
348. Timo, P. (2021). Hallucination: A Mental Illness. Clinical Psychiatry. https://doi.org/10.36648/2471-9854.21.7.81
349. Tito, E., Knapp, B., Bucca, A., & Espiridion, E. D. (2019). A Case Report of Schizoaffective Disorder with Pseudoseizures in a 42-year-old Male. Cureus. https://doi.org/10.7759/cureus.4835
350. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
351. Tollefson, G. D., Souêtre, E., Thomander, L., & Potvin, J. H. (1993). Comorbid anxious signs and symptoms in major depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199300840-00013
352. Torry, Z. D., & Weiss, K. J. (2012). Medication Noncompliance and Criminal Responsibility: Is the Insanity Defense Legitimate?. SSRN Electronic Journal.
353. Torry, Z. D., & Weiss, K. J. (2012). Medication Noncompliance and Criminal Responsibility: Is the Insanity Defense Legitimate?. The Journal of Psychiatry & Law. https://doi.org/10.1177/009318531204000208
354. Townsend, M. C. (2004). Nursing diagnoses in psychiatric nursing : care plans and psychotropic medications. F.A. Davis Co. eBooks.
355. Tp, P., & Ms, D. (1987). [The current understanding of so-called exceptional states in the forensic psychiatry clinic].. PubMed.
356. Treanor, M., & Roemer, L. (2010). Generalized Anxiety Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0379
357. Tunçel, D., Orhan, F. Ö., & Karaaslan, M. F. (2009). The levels of depression and somatization in restless legs syndrome. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
358. Unknown (2017). Brief Psychotic Disorder. The SAGE Encyclopedia of Abnormal and Clinical Psychology. https://doi.org/10.4135/9781483365817.n218
359. Urban‐Kowalczyk, M., Rudecki, T., Wróblewski, D., & Rabe‐Jabłońska, J. (2012). [Psychotic disorders related with chronic use of mephedrone. Case report].. PubMed.
360. Utari, F. P., Suyanti, T. S., & Karyawati, T. (2023). Asuhan Keperawatan Jiwa Pada Tn.M Dengan Masalah Utama Resiko Perilaku Kekerasan Akibat : Skizofrenia Tak Terinci Di Ruang Srikandi RSJD Dr.Amino Gondohutomo Provinsi Jawa Tengah. DIAGNOSA Jurnal Ilmu Kesehatan dan Keperawatan. https://doi.org/10.59581/diagnosa-widyakarya.v1i4.1305
361. Vallejo, J. D. O. (2001). Detecció precoç de la depressió. Revista de la Reial Acadèmia de Medicina de Catalunya.
362. Velleman, S. L., & Mervis, C. Β. (2011). Children With 7q11.23 Duplication Syndrome: Speech, Language, Cognitive, and Behavioral Characteristics and Their Implications for Intervention. Perspectives on Language Learning and Education. https://doi.org/10.1044/lle18.3.108
363. Vitiello, B., Zuddas, A., & Masi, G. (2006). Pharmacologic treatment of children and adolescents with attention deficit hyperactivity disorder. CRC Press eBooks. https://doi.org/10.1201/b14454-11
364. Vloet, J. A., Herpertz‐Dahlmann, B., Hahn, F., Häusler, M., & Holtkamp, K. (2010). Schizophrenieforme Symptomatik bei Chorea minor. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie. https://doi.org/10.1024/1422-4917/a000029
365. Vm, V., & Ns, S. (1983). [Early dysfunctional states in histories of schizophrenic patients].. PubMed.
366. Vn, M. (1989). [Clinical aspects of paroxysmal states in children with depression].. PubMed.
367. Vásquez, R. M. Z., Saracco-Álvarez, R., & Olvera, J. G. (2010). Estimulación magnética transcraneal para síntomas negativos en la esquizofrenia: una revisión. Salud Mental.
368. Walder, D. J., Statucka, M., Daly, M., & Yaffe, B. (2014). Psychotic Disorders. Psychology. https://doi.org/10.1093/obo/9780199828340-0151
369. Walther, M., & Woods, D. W. (2010). Trichotillomania. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1011
370. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
371. Werf-Eldering, M. J. V. D., Schouws, S., Arts, B., & Jabben, N. (2012). [Cognitive dysfunction in bipolar disorder: determinants and functional outcome].. PubMed.
372. Wichaidit, B. T., Rask, C. U., & Østergaard, J. R. (2014). [Diagnosing functional seizures in children and adolescents].. Research Portal Denmark.
373. Wieling, W., Thijs, R. D., Dijk, N. V., Wilde, A. A., Benditt, D. G., & Dijk, J. G. V. (2009). Symptoms and signs of syncope: a review of the link between physiology and clinical clues. Brain. https://doi.org/10.1093/brain/awp179
374. Willis, M. (2020). #WordsMatter—Communicating the voluntary‐to‐involuntary spectrum in conversion disorder. The Brown University Child and Adolescent Behavior Letter. https://doi.org/10.1002/cbl.30460
375. Willner, P. (1984). Drugs, Biochemistry, and Conscious Experience: Toward a Theory of Psychopharmacology. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1984.0009
376. Yakovenko, S., & Rostomova, L. (2016). CONSIDERATION FOR CHILDREN IN CASE OF PARENTS’ DIVORCE. Science and Education. https://doi.org/10.24195/2414-4665-2016-9-36
377. Yamamoto, Y. (2011). Noise and fluctuations in human physiology: Anomalous statistics in health and diseases. https://doi.org/10.1109/icnf.2011.5994395
378. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
379. Yoshimasu, K., Takemura, S., Fukumoto, J., & Miyashit, K. (2012). Self-Reported Symptoms Related to Depression and Suicidal Risk. InTech eBooks. https://doi.org/10.5772/31630
380. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
381. Yu, Y., & Gong, S.-P. (2008). Multiple organ supportive therapy for obstetric multiple organ dysfunction syndrome. https://doi.org/10.3321/j.issn:0376-2491.2008.11.003
382. Yuan, S. (2009). 不能解释的躯体症状的研究进展. Chin J Psychiatry. https://doi.org/10.3760/cma.j.issn.1006-7884.2009.03.019
383. Yung, A. R. (2011). Risk, Disorder and Diagnosis. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.3109/00048674.2011.614926
384. Yutzy, S. H. (2015). Somatic Symptom and Related Disorders: Somatic Symptom Disorder, Illness Anxiety Disorder, and Conversion Disorder. Psychiatry. https://doi.org/10.1002/9781118753378.ch62
385. Yutzy, S. H., & Parish, B. (2008). Somatoform Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch74
386. Zhou, D., & Yuan, T. (2019). Harnessing brain activity at adolescence prevents later schizophrenia development. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.13126
387. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
388. Álvarez, B., Dahlitz, M., Vignau, J., & Parkes, J. D. (1992). The delayed sleep phase syndrome: clinical and investigative findings in 14 subjects.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.55.8.665